BridgeBio Pharma, Inc. APIC, Share-based Payment Arrangement, Option, Increase for Cost Recognition
BridgeBio Pharma, Inc. (BBIO) reported APIC, Share-based Payment Arrangement, Option, Increase for Cost Recognition of $11.75 million for the 3-month period ending 2020-09-30, per its 10-Q filed 2020-11-05.
Discontinued › Shareholders' Equity › Adjustments to Additional Paid in Capital › APIC, Share-Based Payment Arrangement, Increase for Cost Recognition
us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition · last filed 2020-11-05
- BridgeBio Pharma, Inc. apic, share-based payment arrangement, option, increase for cost recognition for the quarter ending 2020-09-30 was $11.75M, a 197.19% increase year-over-year.
- BridgeBio Pharma, Inc. apic, share-based payment arrangement, option, increase for cost recognition for the quarter ending 2020-06-30 was $7.29M, a 233.41% increase year-over-year.
- BridgeBio Pharma, Inc. apic, share-based payment arrangement, option, increase for cost recognition for the quarter ending 2020-03-31 was $8.06M, a 552.35% increase year-over-year.
- BridgeBio Pharma, Inc. apic, share-based payment arrangement, option, increase for cost recognition for the quarter ending 2019-09-30 was $3.95M.
- BridgeBio Pharma, Inc. apic, share-based payment arrangement, option, increase for cost recognition for fiscal 2019 was $3.94M.
| Period end | APIC, Share-based Payment Arrangement, Option, Increase for Cost Recognition 3 month | APIC, Share-based Payment Arrangement, Option, Increase for Cost Recognition 3 month as first filed | APIC, Share-based Payment Arrangement, Option, Increase for Cost Recognition 6 month | APIC, Share-based Payment Arrangement, Option, Increase for Cost Recognition 9 month | APIC, Share-based Payment Arrangement, Option, Increase for Cost Recognition 12 month |
|---|---|---|---|---|---|
| 2020-09-30 | $11.75M 10-Q · filed 2020-11-05 | $19.04M derived: sum of 2 quarters · filed 2020-11-05 | $27.11M derived: sum of 3 quarters · filed 2020-11-05 | ||
| 2020-06-30 | $7.29M 10-Q · filed 2020-11-05 | $15.36M derived: sum of 2 quarters · filed 2020-11-05 | |||
| 2020-03-31 | $8.06M 10-Q · filed 2020-11-05 | ||||
| 2019-12-31 | $3.94M 10-K · filed 2020-03-03 | ||||
| 2019-09-30 | $3.95M 10-Q · filed 2020-11-05 | $1.55M 10-Q · filed 2019-11-08 | $6.14M derived: sum of 2 quarters · filed 2020-11-05 | $7.38M derived: sum of 3 quarters · filed 2020-11-05 | |
| 2019-06-30 | $2.19M 10-Q · filed 2020-11-05 | $3.42M derived: sum of 2 quarters · filed 2020-11-05 | |||
| 2019-03-31 | $1.24M 10-Q · filed 2020-11-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |